Switch to Aflibercept After Chronic Treatment With Bevacizumab for Choroidal Neovascularization With Age-Related Macular Degeneration.

IF 0.5 Q4 OPHTHALMOLOGY
Zofia Anna Nawrocka, Karolina Dulczewska-Cichecka, Michal Zając, Thomas A Galus, Magdalena Trębinska, Jerzy Nawrocki
{"title":"Switch to Aflibercept After Chronic Treatment With Bevacizumab for Choroidal Neovascularization With Age-Related Macular Degeneration.","authors":"Zofia Anna Nawrocka, Karolina Dulczewska-Cichecka, Michal Zając, Thomas A Galus, Magdalena Trębinska, Jerzy Nawrocki","doi":"10.1177/24741264251330334","DOIUrl":null,"url":null,"abstract":"<p><p><b>Purpose:</b> To present the 5-year anatomic and functional outcomes in patients with choroidal neovascularization (CNV) and age-related macular degeneration (AMD) and determine whether late-onset intensification of treatment results in improved outcomes. <b>Methods:</b> This retrospective interventional study analyzed spectral-domain optical coherence tomography data and visual acuity (VA) in eyes where treatment intensification was implemented after a mean of 39 months. Data collected included age, sex, injection frequency, central retinal thickness, type of CNV, and VA. Patients were evaluated every 4 to 10 weeks, depending on the disease activity. <b>Results:</b> Fifty eyes of 50 patients with CNV were evaluated. The mean initial VA was 0.37 Snellen (0.58 logMAR), which improved to 0.44 Snellen (0.47 logMAR) after the first bevacizumab injection. Six months after bevacizumab was switched to aflibercept, the improvement in VA was significant in all groups (<i>P</i> < .05). The VA improved throughout the 6-year observation period, with the greatest improvement in VA after the switch seen in patients who received the most injections (<i>P</i> < .05), had the best initial VA (<i>P</i> < .05), and who experienced a significantly greater improvement in VA after the first bevacizumab injection (<i>P</i> = .01). <b>Conclusions:</b> Increasing the treatment frequency, even after several years of treatment, improved visual outcomes in patients with CNV and AMD who switched from bevacizumab to aflibercept.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251330334"},"PeriodicalIF":0.5000,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11993555/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of VitreoRetinal Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/24741264251330334","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To present the 5-year anatomic and functional outcomes in patients with choroidal neovascularization (CNV) and age-related macular degeneration (AMD) and determine whether late-onset intensification of treatment results in improved outcomes. Methods: This retrospective interventional study analyzed spectral-domain optical coherence tomography data and visual acuity (VA) in eyes where treatment intensification was implemented after a mean of 39 months. Data collected included age, sex, injection frequency, central retinal thickness, type of CNV, and VA. Patients were evaluated every 4 to 10 weeks, depending on the disease activity. Results: Fifty eyes of 50 patients with CNV were evaluated. The mean initial VA was 0.37 Snellen (0.58 logMAR), which improved to 0.44 Snellen (0.47 logMAR) after the first bevacizumab injection. Six months after bevacizumab was switched to aflibercept, the improvement in VA was significant in all groups (P < .05). The VA improved throughout the 6-year observation period, with the greatest improvement in VA after the switch seen in patients who received the most injections (P < .05), had the best initial VA (P < .05), and who experienced a significantly greater improvement in VA after the first bevacizumab injection (P = .01). Conclusions: Increasing the treatment frequency, even after several years of treatment, improved visual outcomes in patients with CNV and AMD who switched from bevacizumab to aflibercept.

贝伐单抗慢性治疗脉络膜新生血管伴老年性黄斑变性后改用阿非利塞普。
目的:介绍脉络膜新生血管(CNV)和年龄相关性黄斑变性(AMD)患者的5年解剖学和功能结局,并确定迟发性强化治疗是否能改善预后。方法:这项回顾性介入研究分析了平均39个月后进行强化治疗的眼睛的光谱域光学相干断层扫描数据和视力(VA)。收集的数据包括年龄、性别、注射频率、中央视网膜厚度、CNV类型和VA。根据疾病的活动性,每4至10周对患者进行评估。结果:对50例CNV患者50只眼进行了评价。平均初始VA为0.37 Snellen (0.58 logMAR),首次注射贝伐单抗后改善至0.44 Snellen (0.47 logMAR)。贝伐单抗转为阿非利西普治疗6个月后,各组患者VA均有显著改善(P P P P = 0.01)。结论:增加治疗频率,即使在治疗数年后,也能改善CNV和AMD患者从贝伐单抗转向阿非利西普的视力结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.20
自引率
16.70%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信